The Brand Name POL Has Generic Salt :: Pantoprazole
POL Is From Company Malar Hc. Priced :: Rs. 45
POL have Pantoprazole is comes under Sub class GERD, of Main Class Gastrointestinal System
Main Medicine Class:: Gastrointestinal System Sub Medicine Class :: GERD,
|Salt Name : OR Generic Name||Form||Price : MRP /Probable||Packing|
Indications for Drugs ::
Peptic ulcer disease, H. pylori infection, Gastro-oesophageal reflux disease, Zollinger-Ellison syndrome, Oesophagitis, Acid-related dyspepsia, NSAID-associated ulceration, ulcer resistant to H2 receptor antagonists, Gastrointestinal (GI) bleeding from stress, Prophylaxis for acid aspiration syndrome during induction of anaesthesia
Drug Dose ::
Adult: PO The usual recommended adult oral dose is 40 mg given once daily, before breakfast. The duration of therapy is ranging from 2-8 weeks. Peptic ulcer: 40 mg/day in the morning. Duration: Duodenal ulceration: 2-4 wk; Benign gastric ulceration: 4-8 wk. GERD: 40 mg tablet, once daily in the morning for 4 to 8 weeks. In resistant ulcers: 40 mg tablet, once daily for 8 weeks. Ulcers induced by NSAIDs: 40 mg tablet once daily, in patients receiving continuous treatment with NSAIDs. GI bleeding from stress or acid peptic diseases: Usual adult oral dosage, if required the dosage may be increased. H. pylori infection: 40 mg twice daily w/ clarithromycin and either amoxicillin or metronidazole. Zollinger-Ellison syndrome: 160 mg tablets per day. Once control of acid secretion has been achieved, the dose should be gradually reduced. Prophylaxis for acid aspiration syndrome during induction of anaesthesia: 40-80 mg tablet should be given the evening before surgery and repeated again the morning of surgery. IV Zollinger-Ellison syndrome and other hypersecretory states As Na salt: 80 mg/day. Max: 240 mg/day in divided doses if rapid control required. GERD; Peptic ulcer As Na salt: 40 mg/day until PO can be resumed. Maintenance therapy Maintenance treatment should involve the lowest dose of the drug. Both 20 and 40 mg doses of Pantoprazole are safe and effective in maintaining patients with healed reflux esophagitis and PUD in remission. Elder patient: No problems with Pantoprazole have been encountered in clinical use in this patient group.
Lactation. Delayed release tablets are contraindicated in patients with known hypersensitivity to any of the formulation.
Drug Precautions ::
Long-term therapy may lead to bacterial overgrowth in the GI tract. Hepatic impairment; monitor liver function regularly (if enzymes increase, discontinue); pregnancy; not recommended in children <18 yr; long term use may lead to atrophic gastritis. patients should be cautioned that pantonix delayed release tablets not split, chewed or crushed. Drug Side Effects ::
Diarrhoea, dizziness, pruritus, skin rashes, GI tract infections, chest pain, headache, nausea, pain, anxiety, hyperglycaemia; malaise or lassitude; myalgia; oedema; insomnia; hyperlipidaemia; flatulence, abdominal pain, constipation, eructation, dyspepsia, rectal disorder; urinary frequency, UTI; abnormalities in liver function; local site reaction; hypertonia, neck pain, weakness; bronchitis, cough, dyspnoea, pharyngitis, rhinitis, sinusitis, upper respiratory tract infection, flu syndrome.
Pregnancy category ::
Drug Mode of Action ::
Pantoprazole is a substituted benzimidazole, and also known as PPI due to its property to block the final step of acid secretion by inhibiting H+/K+ ATPase enzyme system in gastric parietal cell. Both basal and stimulated acid are inhibited.
Drug Interactions ::
Ketoconazole; phenprocoumon, warfarin; atazanavir. Concomitant use of proton pump inhibitors w/ methotrexate may elevate & prolong serum levels of methotrexate &/or its metabolite, possibly leading to methotrexate toxicities.